newsfilter
← Latest News
PR Newswire·

Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy

ROCKVILLE, Md., Jan. 3, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB:RGRX) ("RegeneRx" or "Company"), a clinical-stage drug development company focused on tissue protection, repair, and